Alto Neuroscience, Inc. ANRO

Alto Neuroscience, Inc. reported its second-quarter and first-half 2026 results, recording a wider net loss of US$27.64 million for Q2 and US$53.88 million for the six months ended June 30, 2026, with basic loss per share from continuing operations of US$0.65 and US$1.34, respectively. Despite these larger losses, analysts have maintained a strongly positive stance on Alto Neuroscience, highlighting the progress of its clinical-stage pipeline targeting bipolar depression and major depressive...

Alto Neuroscience stock has delivered a very large gain over the past year, yet the valuation checks currently lean toward the shares looking expensive rather than like a clear bargain. Over the last 12 months, Alto Neuroscience has returned about 9.2x an initial investment, which raises the hurdle for any new buyers who are sensitive to valuation. The expanded development of ALTO-207 and the recent funding that is expected to support operations for several years can help underpin growth...

MOUNTAIN VIEW, Calif., August 12, 2026--Alto Neuroscience, Inc. ("Alto") (NYSE: ANRO), a clinical-stage biopharmaceutical company focused on the development of novel precision medicines for neuropsychiatric disorders, today reported financial results for the quarter ended June 30, 2026, and highlighted recent progress across its pipeline of clinical-stage product candidates.

MOUNTAIN VIEW, Calif., July 13, 2026--Alto Neuroscience, Inc. ("Alto") (NYSE: ANRO), a clinical-stage biopharmaceutical company with a mission to redefine psychiatry by leveraging neurobiology to develop personalized and highly effective treatment options, announced today the pricing of an underwritten registered direct offering of 3,776,436 shares of its common stock at a price of $26.48 per share. All of the shares are being offered by Alto. The gross proceeds from the offering are expected to

We recently compiled a list of the 8 Best Up and Coming Pharmaceutical Stocks to Buy Now. Alto Neuroscience, Inc. (NYSE:ANRO) is one of the best up and coming stocks on our list. On June 15, ALTO highlighted the publication in Nature Medicine of Prime-Praxol, an independent randomized, double-blind, placebo-controlled study evaluating pramipexole, a dopamine agonist, […]

MOUNTAIN VIEW, Calif., June 15, 2026--Alto Neuroscience, Inc. ("Alto") (NYSE: ANRO) today highlighted the publication in Nature Medicine of PRIME-PRAXOL, an independent, randomized, double-blind, placebo-controlled trial of the dopamine agonist pramipexole in patients with mood disorders and clinically significant anhedonia. The study was conducted and independently funded by investigators at Lund University, Sweden.

COPT Defense Properties serves defense and intelligence tenants near secure government hubs. Investors will be closely watching whether that niche can keep supporting growth while much of the office market remains under pressure.

Alto Neuroscience deprioritized its lead asset Thursday, a treatment for cognitive impairment due to schizophrenia. The biotech stock tumbled.

Health care stocks declined late Thursday afternoon with the NYSE Health Care Index dropping 0.6% an

(Updates with the latest stock movement in the headline and the first paragraph.) Alto Neuroscien

Shares of Immunovant, Alto and Oric Pharmaceuticals fell this week on clinical trial updates. Elsewhere, Orca Bio’s cell therapy hit a delay and Korsana entered a reverse merger.